Table 4.

Rates of Complete Cytogenetic Response (All Studies) and Major Molecular Response (CA180-013 Study Only) in Patients With Pre-existing BCR-ABL Mutations Treated With Dasatinib After Loss of Response to Prior Imatinib

	Patients, n/N (%)
Variable	Group 1: Loss of MCyR	Group 2: Loss of MCyR and CHR	Group 3: Loss of CHR
CCyR
No BCR-ABL mutation	51/75 (68)	5/10 (50)	8/26 (31)
Any BCR-ABL mutation	46/60 (77)	9/20 (45)	19/77 (25)
T315I	0/2 (0)	0/1 (0)	0/1 (0)
F317L	1/1 (100)	–	0/4 (0)
F359C/I/V	8/8 (100)	–	1/6 (17)
P-loop region*	13/19 (68)	2/7 (29)	7/30 (23)
L248V	1/2 (50)	–	2/6 (33)
G250E	5/6 (83)	1/4 (25)	1/12 (8)
Q252H	0/1 (0)	–	1/2 (50)
Y253F/H	6/8 (75)	1/1 (100)	2/8 (25)
E255K/V	1/2 (50)	0/2 (0)	1/4 (25)
Sample unavailable	11/16 (69)	0/3 (0)	1/6 (17)
MMR
No BCR-ABL mutation	13/24 (54)	1/3 (33)	5/12 (42)
Any BCR-ABL mutation	13/21 (62)	4/13 (31)	8/35 (23)
Sample unavailable	2/2 (100)	0/1 (0)	0/3 (0)

MCyR indicates major cytogenetic response; CHR, complete hematologic response; CCyR, complete cytogenetic response; T315I, threonine-to-isoleucine mutation at codon 315; F317L, phenylalanine-to-leucine mutation at codon 317; F359C/I/V, phenylalanine-to-cysteine, valine, or isoleucine mutation at codon 359; P-loop, adenosine triphosphate phosphate-binding loop; L248V, leucine-to-valine mutation at codon 248; G250E, glycine-to-glutamic acid mutation at codon 250; Q252H, glutamine-to-histidine mutation at codon 252; Y253F/H, tyrosine-to-phenylalanine or histidine mutation at codon 253; E255K/V, glutamic acid-to-lysine or valine mutation at codon 255; MMR, major molecular response.

^*Residues 248 through 256.